Medidata Solutions Announces Definitive Agreement to Acquire Clinical Force
Medidata Solutions announced that it has entered into a definitive agreement to acquire Clinical Force for undisclosed proceeds.The acquisition is subject to various standard closing conditions and is expected to be completed early in Medidata’s fiscal third quarter ending September 30, 2011.
Research sponsors and contract research organizations (CROs) are increasingly looking to reduce the financial and operational management burden of clinical trials, streamline clinical processes and increase visibility to timely information that enhances governance and decision-making. While software systems aiming to address these business challenges have typically required complex implementation projects with large upfront investments, lengthy timelines and ongoing maintenance costs, Clinical Force’s alternative CTMS solution eliminates these risks, providing a proven technology to customers over the past seven years.
Based in the UK, with customers in North America, Europe and India including more than a dozen CROs, Clinical Force has successfully enabled its customers to readily adopt CTMS with a low-risk solution that is quick-to-deploy, easy-to-use, flexible and modular. Research organizations large and small can selectively and rapidly automate a wide range of processes, including time and expense management, milestone tracking, monitoring reports and clinical investigator payments. Current Clinical Force revenue is not material to Medidata in 2011, but it is expected to grow based on access to Medidata’s global capabilities.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Making the Grade: Registries as Sources of Regulatory-Grade Real-World Evidence (RWE)
February 13th 2025Dr. Peter Wahl, MLA, MS, ScD, VP and Global Head of Scientific Affairs at CorEvitas, part of the PPD™ clinical research business of Thermo Fisher Scientific, discusses the critical role of protocol-driven registries in generating regulatory grade RWE to serve multiple and evolving evidence needs across the drug development life cycle. He covers key considerations for selecting the right type of registry, the advantages over EMR datasets, and how registry data contextualizes safety and effectiveness to fulfill FDA and EMA post-marketing requirements.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.
